LI
NTLA icon

Louisbourg Investments’s Intellia Therapeutics NTLA Stock Holding History

Louisbourg Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38K Hold
200
– – ﹤0.01% 186
2026
Q1 		$2.56K Hold
200
– – ﹤0.01% 194
2025
Q4 		$1.8K Buy
+200
New +$2.75K ﹤0.01% 196

Other funds holding NTLA

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Louisbourg Investments's NTLA Position: Q2 2026 in Review

Louisbourg Investments held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 200 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #186.

Louisbourg Investments first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Louisbourg Investments held 200 shares of Intellia Therapeutics worth $3.38K as of Q2 2026.
  • Louisbourg Investments left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Louisbourg Investments's portfolio in Q2 2026, its #186 holding.
  • Louisbourg Investments first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Louisbourg Investments's 13F filing for Q2 2026, filed 23 Jul 2026.